CTLA4 and lung carcinoma: CTLA‐4 and PD‐1 inhibitors can be used to stimulate the T cells in COPD to mitigate the risk of disease progression and lung cancer, but the activation of cytotoxic T cells can influence the development of emphysema via the apoptosis of structural cells.